Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells
- 1 August 2002
- journal article
- clinical trial
- Published by Elsevier BV in The Lancet
- Vol. 360 (9331), 436-442
- https://doi.org/10.1016/s0140-6736(02)09672-1
Abstract
No abstract availableThis publication has 21 references indexed in Scilit:
- Biology and disease associations of Epstein–Barr virusPhilosophical Transactions Of The Royal Society B-Biological Sciences, 2001
- Role of Cytotoxic T Lymphocytes in Epstein-Barr Virus-Associated DiseasesAnnual Review of Microbiology, 2000
- Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantationThe Lancet, 1999
- Clinical and pathological features of post-transplant lymphoproliferative disorders (PTLD)Springer Seminars in Immunopathology, 1998
- Activation antigen expression on human T cells. I. Analysis by two-colour flow cytometry of umbilical cord blood, adult blood and lymphoid tissueClinical and Experimental Immunology, 1996
- Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferationThe Lancet, 1995
- Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein-Barr virus in late disease.The Journal of Experimental Medicine, 1993
- Restoration of Viral Immunity in Immunodeficient Humans by the Adoptive Transfer of T Cell ClonesScience, 1992
- Enzymatic Amplification of β-Globin Genomic Sequences and Restriction Site Analysis for Diagnosis of Sickle Cell AnemiaScience, 1985
- Transformation of foetal human leukocytes in vitro by filtrates of a human leukaemic cell line containing herpes‐like virusInternational Journal of Cancer, 1968